Fulcrum Therapeutics Inc (FULC) - Total Assets
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) holds total assets worth $214.86 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Fulcrum Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Fulcrum Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Fulcrum Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Fulcrum Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Fulcrum Therapeutics Inc's total assets of $214.86 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.3% |
| Accounts Receivable | $3.34 Million | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Fulcrum Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fulcrum Therapeutics Inc's current assets represent 95.9% of total assets in 2024, an increase from 30.8% in 2017.
- Cash Position: Cash and equivalents constituted 22.3% of total assets in 2024, up from 9.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Fulcrum Therapeutics Inc Competitors by Total Assets
Key competitors of Fulcrum Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Fulcrum Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.70 | 18.44 | 4.23 |
| Quick Ratio | 17.70 | 18.44 | 4.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $194.23 Million | $252.98 Million | $86.19 Million |
Fulcrum Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Fulcrum Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.54 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | $260.72 Million |
| Market Capitalization | $230.90 Million USD |
Valuation Analysis
Near Book Valuation: The market values Fulcrum Therapeutics Inc's assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Fulcrum Therapeutics Inc's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Fulcrum Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $260.72 Million | +1.17% |
| 2023-12-31 | $257.69 Million | +13.68% |
| 2022-12-31 | $226.69 Million | -3.54% |
| 2021-12-31 | $235.00 Million | +81.36% |
| 2020-12-31 | $129.58 Million | +17.33% |
| 2019-12-31 | $110.44 Million | +28.76% |
| 2018-12-31 | $85.77 Million | +1876.29% |
| 2017-12-31 | $4.34 Million | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more